Toxicity from treatment of neuroblastoma with 131 I-meta-iodobenzylguanidine
dc.contributor.author | Mallette, Shirley A. | en_US |
dc.contributor.author | Carey, James E. | en_US |
dc.contributor.author | Hutchinson, Raymond J. | en_US |
dc.contributor.author | Shapiro, Brahm | en_US |
dc.contributor.author | Johnson, Jon W. | en_US |
dc.contributor.author | Wieland, Donald M. | en_US |
dc.contributor.author | Sisson, James C. | en_US |
dc.date.accessioned | 2006-09-11T18:15:05Z | |
dc.date.available | 2006-09-11T18:15:05Z | |
dc.date.issued | 1988-09 | en_US |
dc.identifier.citation | Sisson, James C.; Hutchinson, Raymond J.; Carey, James E.; Shapiro, Brahm; Johnson, Jon W.; Mallette, Shirley A.; Wieland, Donald M.; (1988). "Toxicity from treatment of neuroblastoma with 131 I-meta-iodobenzylguanidine." European Journal of Nuclear Medicine 14 (7-8): 337-340. <http://hdl.handle.net/2027.42/46827> | en_US |
dc.identifier.issn | 1619-7089 | en_US |
dc.identifier.issn | 0340-6997 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46827 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3181182&dopt=citation | en_US |
dc.description.abstract | Toxic effects from 131 I-meta-iodobenzylguanidine ( 131 I-MIBG) treatments of neuroblastoma in six patients were recorded. The toxicity was largely confined to the hematologic system where circulating leukocytes and platelets regularly declined after each dose of 131 I-MIBG; the values reached nadirs between three and seven weeks and recovered slowly over subsequent weeks. Prior bone marrow transplantation and infiltration of bone marrow by neuroblastoma appeared to make the hematologic system more vulnerable to the radiation. Dosimetry revealed greater absorbed radiation by the whole body than by the blood and bone marrow. These observations are explained by a relatively rapid exit of 131 I-MIBG from the blood to other tissues (but not to the bone marrow). Since treatment of an aggressive and lethal tumor such as neuroblastoma should be pushed to a degree of toxicity, careful dosimetry in each case will be necessary as a guide to reach the point of maximally tolerable toxicity. | en_US |
dc.format.extent | 424961 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Imaging / Radiology | en_US |
dc.subject.other | Meta-iodobenzylguanidine | en_US |
dc.subject.other | Neuroblastoma | en_US |
dc.subject.other | Nuclear Medicine | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Radiation Toxicity | en_US |
dc.subject.other | Bone Marrow | en_US |
dc.title | Toxicity from treatment of neuroblastoma with 131 I-meta-iodobenzylguanidine | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Physics | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Division of Hematology-Oncology, Department of Pediatrics, The University of Michigan Medical Cener, 48109, 0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Division of Nuclear Medicine, Department of Internal Medicine, The University of Michigan Medical Center, 48109, 0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 3181182 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46827/1/259_2004_Article_BF00254379.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00254379 | en_US |
dc.identifier.source | European Journal of Nuclear Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.